Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients

Oncology

Volumn 63, Issue 4, 2002, Pages 370-377

  Mandal̀, Mario ^a   Lissoni, Paolo ^b   Ferretti, Gianluigi ^c   Rocca, Andrea ^d   Torri, Valter ^d   Moro, Cecilia ^e   Curigliano, Giuseppe ^d   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c SANTA MARIA GORETTI HOSPITAL   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e IRCCS   (Italy)

Author keywords

Breast cancer, node negative; Hyperprolactinemia

Indexed keywords

ESTRIOL; GROWTH HORMONE; PROLACTIN;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GONAD; HORMONE DETERMINATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOASSAY; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; STRESS; TIME; VENOUS BLOOD;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RISK FACTORS;

EID: 0036967959     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066228     Document Type: Article

References (25)

1. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988;15:20-25.
2. Silvestrini R, Dandone MG, Luisi A, et al: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995;13:697-704.
3. Goffin V, Touraine P, Pitchard C, et al: Should prolactin be considered as a therapeutic target in human breast cancer? Mol Cell Endocrinol 1999;151:79-87.
4. Vonderhaar BK: Prolactin involvement in breast cancer. Endocr Relat Cancer 1999;6: 389-404.
5. Spady TJ, Harvell DM, Snyder MC, et al: Estrogen-induced tumorigenesis in the Copenhagen rat: Disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinoma. Cancer Lett 1998; 13:95-103.
6. Harvell DM, Strecker TE, Tochacek M, et al: Rat strain-specific actions of 17beta-estradiol in the mammary gland: Correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 2000; 14:2779-2784.
7. Patel DD, Bhatavdekar JM, Chikhlikar PR, et al: Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:86-92.
8. Lissoni P, Barni S, Ardizzoia A, et al: Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion. Oncology 1995;52:439-442.
9. Boyns AR, Buchan R, Cole EN, et al: Basal prolactin blood levels in three strains of rat with differing incidence of 7,12-dimethylbenz(a)antracene-induced mammary tumors in rats. Eur J Cancer 1973;9:169-171.
10. Welsch CW, Griber C: Prophylaxis of spontaneously developing mammary carcinoma in C3H/HeJ female mice by suppression of prolactin. Cancer Res 1973;33:2936-2946.
11. Welsch CW, Nagasawa H: Prolactin and murine mammary tumorigenesis: A review. Cancer Res 1977;37:951-963.
12. Patel DD, Bhatavdekar JM, Chikhlikar PR, et al: Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62/2:86-92.
13. Bhatavdekar JM, Patel DD, Vora HH, et al: Node positive breast cancer: Prognostic significance of the plasma prolactin compared with steroids receptors and clinicopathological features. Oncol Rep 1994;1:841-845.
14. Martini JF, Piot C, Humeau LM, Struman I, et al: The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 2000;14: 1536-1549.
15. Barni S, Lissoni P, Fumagalli L, et al: Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994;80: 212-215.
16. Gordts SL, Neven P, Van Hooff I, et al: The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue. Eur J Cancer 2000; 36(suppl 4):S20-21.
17. Hanna W, Mobbs BG: Comparative evaluation of ER-ICA and enzyme immunoassay for the quantitation of estrogen receptors in breast cancer. Am J Clin Pathol 1989;91/2:182-186.
18. Lapidus RG, Nass SJ, Davidson NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3/1:85-94.
19. Leers MP, Nap M: Steroid receptor heterogeneity in relation to DNA index in breast cancer: A multiparameter flow cytometric approach on paraffin-embedded tumor samples. Breast J 2001;7/4:249-259.
20. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
21. Wang DY, Hampson S, Kwa HG, et al: Serum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 1986;22:487-492.
22. Fisher B, Redmond C, Fisher ER, et al: Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical and Bowel Project (NSABP) Protocol B-06. J Clin Oncol 1988;6:1076-1087.
23. Arriagada R, Rutqvist LE, Skoog L, et al: Prognostic factors and natural history in lymphnode negative breast cancer patients. Breast Cancer Res Treat 1992;21:101-109.
24. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
25. Loprinzi CL, Thome SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972-979.